Drug Approval | November 08, 2025
Zydus Lifesciences secures FDA tentative approval for Olaparib tablets
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Marks first international filing for Evofem’s single-dose oral treatment
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Subscribe To Our Newsletter & Stay Updated
